Julie Kim, current president of Takeda's U.S. Business Unit, appointed as successor to CEO Christophe Weber, effective June 2026.346
Christophe Weber to retire in June 2026 after 12 years leading Takeda, during which revenue nearly doubled and the company became a global R&D-driven biopharmaceutical firm.1346
Takeda announced organizational structure and executive leadership changes for FY2026 starting April 1, 2026, to enhance speed, competitiveness, and growth.2
On March 25, 2026, Takeda approved transformation steps expected to deliver over JPY 200 billion in annualized gross savings by FY2028.5
Julie Kim will be proposed for election to Takeda's Board at the June 2026 Annual General Shareholders Meeting.34
Sources:
1. https://www.takeda.com/our-impact/our-stories/shaping-a-bold-new-chapter/
2. https://www.takeda.com/newsroom/newsreleases/2026/changes-to-organizational-structure-and-executive-leadership-team-for-fy2026/
3. https://www.takeda.com/newsroom/newsreleases/2025/julie-kim-appointed-successor-ceo/
4. https://www.businesswire.com/news/home/20250129509380/en/Julie-Kim-Will-Succeed-Christophe-Weber-as-CEO-of-Takeda-in-June-2026
5. https://www.takeda.com/newsroom/newsreleases/2026/takeda-transformation-strengthen-competitiveness-future-growth/
6. https://www.fiercepharma.com/pharma/takeda-tabs-julie-kim-take-over-retiring-ceo-christophe-weber